Rapid Analysis of Outcomes Using the Systemic Anti-Cancer Therapy (SACT) Dataset

R Pathak; M Wallington; C Saunders; M Braun; S Mullamitha; G Wilson; J Hasan; D Dodwell; M Bomb; M Saunders

doi:10.1016/j.clon.2017.02.011

Rapid Analysis of Outcomes Using the Systemic Anti-Cancer Therapy (SACT) Dataset

Clin Oncol (R Coll Radiol). 2017 Jul;29(7):e134-e136. doi: 10.1016/j.clon.2017.02.011. Epub 2017 Mar 18.

Authors

R Pathak¹, M Wallington², C Saunders³, M Braun⁴, S Mullamitha⁴, G Wilson⁴, J Hasan⁴, D Dodwell⁵, M Bomb², M Saunders⁴

Affiliations

¹ University of Manchester, Manchester, UK. Electronic address: ryan.pathak@manchester.ac.uk.
² National Cancer Registration and Analysis Service, Public Health England, London, UK.
³ St Andrews Medical School, St Andrews, UK.
⁴ The Christie NHS Foundation Trust, Manchester, UK.
⁵ Leeds Teaching Hospitals NHS Trust, Leeds, UK.

PMID: 28320583
DOI: 10.1016/j.clon.2017.02.011

Abstract

We audited the accuracy of the Systemic Anti-Cancer Therapy dataset as a resource for rapid analysis of outcomes for patients, in this example, receiving Cancer Drug Fund funded monoclonal antibodies to treat metastatic colorectal cancer. We concluded that the Systemic Anti-Cancer Therapy dataset is a potentially valuable resource for rapidly determining survival outcome for patients treated with chemotherapy.

Keywords: CDF; Cancer Drug Fund; SACT; Systemic Anti-Cancer Therapy dataset; cetuximab; colorectal.

MeSH terms

Antineoplastic Agents / therapeutic use*
Cetuximab / therapeutic use*
Colorectal Neoplasms / drug therapy*
Female
Humans
Male
Treatment Outcome

Substances

Antineoplastic Agents
Cetuximab